Lexapro (escitalopram) is one of the most effective and best-tolerated antidepressants available, with clinical trials showing roughly 73% of patients responding to treatment and about 66% achieving full remission of depression symptoms. It belongs to the SSRI class of medications and is FDA-approved for two conditions: major depressive disorder in adults and adolescents 12 and older, and generalized anxiety disorder in adults.
How Lexapro Works in the Brain
Lexapro increases serotonin levels by blocking the protein that reabsorbs serotonin after it’s released between brain cells. What makes it unusual among SSRIs is how it attaches to this protein. Most SSRIs bind to a single site on the serotonin transporter. Lexapro binds to that same site but also locks onto a second site nearby, which slows down its own detachment from the transporter. The result is a more sustained blockade of serotonin reuptake compared to other medications in its class.
This dual-binding mechanism is one reason Lexapro can work at relatively low doses. Most people take just 10 mg once daily, and many never need to increase beyond that. The maximum dose is 20 mg, which a doctor might consider after at least a week if the starting dose isn’t providing enough relief.
Stronger Results Than Other SSRIs
A meta-analysis of nearly 2,700 patients found that Lexapro outperformed other common SSRIs, including fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), and citalopram (Celexa). Patients on Lexapro were 31% more likely to respond to treatment compared to those on other SSRIs. The advantage was even more pronounced in people with severe depression: Lexapro patients were twice as likely to respond and 56% more likely to reach full remission than those taking other SSRIs.
In a large primary-care study, 72.5% of patients on Lexapro met the threshold for treatment response, meaning their depression symptoms dropped by at least half. Full remission, where symptoms essentially resolve, was reached by 65.5% of patients. These are strong numbers for any antidepressant, and they help explain why Lexapro is often a first-line choice.
Better Tolerability and Fewer Dropouts
One of Lexapro’s clearest advantages is that fewer people quit taking it because of side effects. In pooled clinical data, only 6.7% of Lexapro patients stopped treatment due to adverse events, compared to 9.1% for other antidepressants. When citalopram (its close chemical relative) was excluded from the comparison, the gap widened further: 6.8% for Lexapro versus 10.7% for other SSRIs.
That doesn’t mean Lexapro is side-effect-free. Common side effects, reported by more than 1 in 100 people, include nausea, headaches, dry mouth, excessive sweating, insomnia or drowsiness, and general fatigue. Most of these tend to be mild and often fade within the first few weeks as your body adjusts.
What the First Weeks Look Like
Lexapro raises serotonin levels within hours of your first dose, but that doesn’t translate to immediate mood improvement. The brain needs time to adapt to the new chemical environment. The typical timeline breaks down into two phases.
Physical and behavioral changes tend to come first. Improvements in sleep quality, energy levels, and appetite can appear within one to two weeks. These early shifts are often the first sign the medication is working, even if your mood hasn’t changed yet.
Emotional symptoms take longer. Relief from persistent sadness, loss of interest in activities, or the heavy mental fog of depression generally takes six to eight weeks to fully develop. This lag can be frustrating, but it’s normal and doesn’t mean the medication isn’t working. Sticking with treatment through this window is important, since many people who quit early would have responded if they’d continued.
Long-Term Benefits and Relapse Prevention
Lexapro’s benefits extend well beyond the initial weeks of treatment. Staying on the medication after symptoms improve significantly reduces the chance of relapse. In a study of patients who responded well to 12 weeks of Lexapro, those who continued taking it relapsed only 22% of the time over the following six months. Patients switched to a placebo relapsed 50% of the time. Put another way, stopping treatment nearly tripled the risk of symptoms returning.
Patients who stayed on Lexapro didn’t just hold steady. They continued to improve over time, showing further gains in symptoms and daily functioning during the maintenance phase. The medication remained well-tolerated throughout, with 65% of Lexapro patients completing the full six-month continuation period compared to 41% on placebo.
Benefits for Anxiety
While many people associate Lexapro primarily with depression, its FDA approval for generalized anxiety disorder reflects genuine effectiveness for chronic, hard-to-control worry. The same serotonin-boosting mechanism that lifts depression also helps calm the overactive worry circuits involved in GAD. For people dealing with both depression and anxiety simultaneously, which is extremely common, Lexapro can address both conditions with a single medication.
Lexapro has also shown benefits for social anxiety disorder in clinical research. In a study where patients with social anxiety responded to 12 weeks of treatment, continued use cut relapse risk by more than half compared to stopping the medication. Though social anxiety is not an official FDA-approved indication, these results reflect the medication’s broad reach across anxiety-related conditions.
Simple Dosing
Lexapro’s once-daily dosing is a practical advantage that’s easy to overlook. The standard dose of 10 mg works for most adults, adolescents, and elderly patients. There’s no complicated titration schedule. If an increase to 20 mg is needed, it’s a single step up. For people with liver problems, the recommended dose stays at 10 mg, and no adjustment is needed for mild or moderate kidney impairment. This simplicity makes it easier to take consistently, which directly affects how well any medication works in practice.